View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
October 23, 2020

Coronavirus company news summary – Gilead’s remdesivir is approved by the FDA – Roche and Atea team up on Covid-19 DAA

By Allie Nawrat

23 October 2020 

The US Food and Drug Administration has approved Gilead Sciences’ antiviral drug Veklury (remdesivir) to treat hospitalised Covid-19 patients. Veklury stops the replication of the SARS-CoV-2 virus that caused Covid-19. It is the first and the only approved drug for Covid-19 in the US and is abundantly available due to early investment efforts by the country to maximise its supply.

Roche and Atea Pharmaceuticals have collaborated to develop the AT-527, an oral direct-acting antiviral (DAA) for Covid-19. AT-527 blocks the viral RNA polymerase enzyme and is currently in Phase II trials for hospitalised Covid-19 patients suffering with moderate symptoms. The antiviral drug will also undergo a phase 3 trial to understand its use in patients outside hospitals and in post-exposure preventive scenario.

The International AIDS Vaccine Initiative and the Serum Institute of India have entered into an agreement with Merck to develop SARS-CoV-2 neutralising monoclonal antibodies (mAbs) to fight the Covid-19 disease. The mAbs have been co-invented by IAVI and Scripps Research; this partnership is unique because it ensures equitable global access to innovative therapies for Covid-19.

The San Antonio Medical Foundation has awarded a grant to Doug E. Frantz, a researcher from the University of Texas at San Antonio to support his work on a novel Covid-19 drug. Frantz will be assisted in his research by the UT Health San Antonio and Southwest Research Institute.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology